CN1942185A - Treatment of impaired respiratory function with gaboxadol - Google Patents
Treatment of impaired respiratory function with gaboxadol Download PDFInfo
- Publication number
- CN1942185A CN1942185A CNA2005800119819A CN200580011981A CN1942185A CN 1942185 A CN1942185 A CN 1942185A CN A2005800119819 A CNA2005800119819 A CN A2005800119819A CN 200580011981 A CN200580011981 A CN 200580011981A CN 1942185 A CN1942185 A CN 1942185A
- Authority
- CN
- China
- Prior art keywords
- purposes
- sleep apnea
- gaboxadol
- treatment
- sleep
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a method for treating impaired respiratory function in a human patient suffering from sleep apnea, such as central sleep apnea or obstructive sleep apnea, comprising administering to said patient an effective amount of gaboxadol per day.
Description
Invention field
The present invention relates to gaboxadol (gaboxadol) preparation be used for the treatment of suffer from such as centric sleep apnea or obstructive sleep apnea the medicine of human patients respiratory function damage of sleep apnea (sleepapnea) aspect purposes and the method for the treatment human patients respiratory function damage of suffering from sleep apnea.
Background of invention
No matter under awakening or sleep state, upper respiratory tract is unobstructed all is the essential condition of breathing.Over the last couple of decades, studies confirm that the syndromic existence of a kind of complexity in a large number, be characterized in only under sleep state, taking place unusual low airway open, and therefore caused abnormal breathing.The patient is if one or more in these symptoms, and the breathing under its sleep state will withering or block and present part or all of asphyxia because of upper respiratory tract.
At present, the treatment to sleep apnea generally includes mandibular bone orthotics and secular nasal cavity continuous positive airway pressure (nCPAP) in upper respiratory tract operation, the oral cavity.These methods are all very loaded down with trivial details, toleration difference and/or very expensive.Different medicines such as tricyclic antidepressant, selective serotonin reuptake inhibitor and Progesterone also are applied to this type of treatment of diseases, but not seen widespread use is in clinical because its curative effect is limited.Respiratory stimulant theophylline and azetazolamide, carbonic anhydrase inhibitors also are used to treat in the experimental research of centric sleep apnea (CSA), but are not applied to clinical treatment as yet.
In WO00/51590, the various mechanical systems that are used to prevent or improve sleep-related breathing disorders are disclosed.The GABA receptor stimulating agent it is said it is useful in addition, and the example of mentioning has isoguvacine, 5-aminomethyl-3-hydroxyisoxazole, THIP, piperidines-4-sulfonic acid, flunitrazepam, zolpidem, abecarnil, baclofen, piracetam and progabide.But this wherein has some is not the GABA receptor stimulating agent.
(4,5,6, the different azoles of 7-tetrahydrochysene also (5,4-c) pyridine-3-alcohol) has great potentiality to the treatment sleep disordered breathing to gaboxadol among EP patent 0000338B1 and the EP patent 0840601B1.
Invention is described
The respiratory function that the human patients of sleep apnea has damaged is badly in need of new effective treatment means.Especially, medicine all has more advantage to this class treatment of diseases than existing intrusion or non-invasive Therapeutic Method, because many existing means can only part relief of symptoms and too loaded down with trivial details for the patient.
The human patients of suffering from sleep apnea usually can be simultaneously with depression, and the patient who perhaps suffers from depression understands sleep respiratory disorder occurred frequently.Therefore, have reason to believe that this class patient is badly in need of property respiratory disorder of treatment sleep simultaneously and depression.
Treat apneic brainstrust it has been generally acknowledged that sleep apnea be divided into three kinds dissimilar: obstructive type, maincenter type and mixed type.In these three kinds, obstructive sleep apnea (OSA) is modal; Centric sleep apnea (CSA) is relatively more rare; And mixed type is meant to have above-mentioned two kinds of characteristics simultaneously, and its therapeutic modality is identical with OSA.
The obstructive sleep apnea characteristics are because the repeated asphyxia that upper respiratory tract (throat) blocks and/or withers and cause between sleep period descends to causing then to breathe with blood oxygen saturation usually and recovers.This is known as apnea.Respiratory effort continues always in accidental apnea.Play an analogy, OSA is just as the suction inlet that your hands is placed on vacuum cleaner.Even vacuum cleaner still sucks (respiratory effort continues) in the trial that does not stop, your hands still can hinder pass through (upper airway collapse) of all air-flows.Vacuum cleaner can use in this case usually as possible, and human body also is the same.
Centric sleep apnea is a respiratory effort stop conditions between a kind of neuropathic sleep period, follows the decline of blood oxygen saturation usually.Get back to the metaphor of vacuum cleaner: central respiratory arrest just looks like to be the plug that has taken out vacuum cleaner.Do not have power supply, do not have to suck:, just breathe no more yet and make great efforts and breathed if the brain stem maincenter of control breathing stops.The patient will be waken up from sleep because of the autonomous respiration reflection, so this class patient's sleep usually seldom.
At context of the present invention, the obstruction of mentioning in the description does not comprise for example obstruction that causes of mucus of foreign body or slop.The simple form of part airway collapse or obstruction is exactly the thick and heavy and strong sound of snoring.It is shallow excessively that more airway collapse or obstruction show as a kind of bradypnea, and promptly respiratory air flow significantly reduces the reduction of following or do not follow blood oxygen concentration.The form that obstructive apnea is the most serious, i.e. the state that withers fully of upper respiratory tract, more commonly the patient still keeps respiratory effort when multiple accidental airway obstruction.The minimizing of air-flow finally causes hypoxemia, hemodynamics variation and waking up.And cardiovascular complication is very general in obstructive sleep apnea, and insulin resistance, diabetes, obesity, the lipid metabolism that obstructive sleep apnea occurs together to be increased changes and platelet aggregation power increases.It should be noted that it is to occur that above-mentioned symptom and complication have more than in the patient with severe symptoms.In the partial sleep apnea patient that regular hypoxemia and serious snoring only occur, also observe similar symptom.
Confirmed that several factors all is to cause the procatarxis of airway collapse in the sleep.Short and small comprising obesity, upper respiratory tract tissue loose (especially child) and lower jaw.Yet great majority are slight, there is not above-mentioned factor in the sleep apnea patient of moderate or severe, therefore are considered to former sleep apnea (essential sleep apnoea).And the constitutional sleep apnea seemingly causes owing to central nervous mechanisms, be to keep the unobstructed muscle neural activity decline of upper respiratory tract in the sleep to cause.These mechanism may also be the major reasons that above-mentioned procatarxis sexual factor causes and increase the weight of sleep disordered breathing.
Yet obviously the disappearance of unusual anatomic factor is not got rid of the dynamic malfunction of tongue and upper respiratory tract dilator.This functional defect may originate from the central nervous system, promptly causes to the signal level of conduction of periphery muscle or MNJ.As if this control defective is only remarkable especially when sleep, and nervus centralis, peripheral nervous and/or MNJ that upper respiratory tract is controlled in prompting in this state are interfered especially easily.In addition, it is important that the healthy elasticity of upper respiratory tract will finally resist the airway collapse power that is caused by respiratory air flow in the air flue.A kind of feature of situation is the tangible chemoreflex activation of appearance (chemoreflex activation) thereby causes high ventilation drive, to optimize the high chance that sucks air-flow.If this potential power of withering is resisted by unusual low air flue elasticity, air flue will tend to wither.This potential mechanism is especially noticeable in the particular form of some sleep disordered breathings, as CA, periodic breathing and/or Cheyne-Stokes respiration (all being meant centric sleep apnea at this).The characteristics of this respiratory disorder form are to breathe by the oscillatory type of a large amount of chemoreflex property activation cycle driving.
The stability of ventilation control depends on some factors in the event circle of keeping the metabolism homeostasis.This event circle comprise central controller gain (controller gain) (comprise the replying of chemoreceptor, brain stem respiratory center reply and excited) and a series of implantation factor (plantfactors), latter's decision is changed by ventilation and causes the degree of mixed type pulmonary capillary gas tension change.Also have some factors at last, latter's decision is to mixing the change of the given pulmonary capillary gas tension that change caused of pulmonary capillary gas tension.These factors comprise the diffusion delays that pulmonary circulation postpones and relate in the chemoreflex feedback.This " loop gain (loopgain) " or feedback control degree comprise all factors that periodic breathing sensitivity assessment basis is provided.When loop gain was changed into certain value, consistent unstability will produce, and this change all may produce in any step of loop.In this sense, can think that the multi-form sleep apnea that comprises central and obstructive may have similar main pathogenetic background.In some cases, changing may appear significantly when sleep disordered breathing not occurring in gain, and there is high stability respiratory control system in prompting.In other central respiratory arrest, the slight change of gain can be diseases induced, and control system to hint has the tendency of vibration.The tendentiousness of this increase more is more common in such as heart failure and upper respiratory tract bore height and is depended on the activity of upper respiratory tract dilator to keep the patient of ventilation.In addition, sleep itself, especially REM sleep it seems in some sleep disordered breathing patients it is very important loop gain regulatory factor.Therefore, will change the characteristic of this loop effectively, and reduce or the elimination sleep disordered breathing based on the treatment means of regulating one or several link in the cyclic system.
An object of the present invention is provides effective treatment for the human patients that the respiratory function of suffering from sleep apnea damages; particularly centric sleep apnea or obstructive sleep apnea or their mixing, its minimizing and/or eliminated some or all shortcomings of means known in the art.
Another object of the present invention is to provide effective treatment, particularly long-term treatment for the human patients of suffering from sleep apnea.
Another object of the present invention is not provide effective treatment, particularly long-term treatment for having abuse or relying on the human patients for the treatment of.
Another object of the present invention is to provide effective treatment for the human patients of suffering from sleep apnea and suffering from depression simultaneously.
Other purpose of the present invention can be apparent after reading description of the present invention.
The general formula of gaboxadol is
And " gaboxadol " is meant any form that comprises described chemical compound in description full text, this alkali (amphion) for example, pharmaceutically acceptable salt, for example, pharmaceutically-acceptable acid addition, the hydrate of alkali or salt or solvate, and dehydrate and unbodied or crystalline form.
The treatment of respiratory function damage is meant the respiratory function damage patient that suffers from sleep apnea in length of one's sleep of 10 minutes to 10 hours for example, and symptom improves or alleviates.
Typically, this is treated less than week age (short term therapy), 1 to 4 week (intermediate period treatment) or surpass around the time (long-term treatment).A particular type of long-term treatment is a chronic treatment.
Term " old age " was meant 65 years old and the above mankind.
Term " adult " is meant 18 to 64 years old the mankind.
According to the present invention, the active drug that does not have apparent side effect that the human patients respiratory function that provides treatment to suffer from sleep apnea damages, sleep apnea is for example central sleep apnea or obstructive sleep apnea.
Aspect wide region, the present invention relates to the purposes aspect gaboxadol is used for the treatment of sleep apnea in preparation the medicine of human patients.
On the other hand, the present invention relates to the purposes aspect gaboxadol is used for the treatment of sleep apnea in preparation the medicine of human patients respiratory function damage, described sleep apnea is for example centric sleep apnea or obstructive sleep apnea.
In one embodiment, sleep apnea is the mixing of centric sleep apnea and obstructive sleep apnea.
In another embodiment, the patient suffers from depression and sleep apnea simultaneously.
In another embodiment, gaboxadol has increased patient's S sleep and has therefore improved respiratory function.
In another embodiment, gaboxadol is acid-addition salts or amphion hydrate or amphion dehydrate.In further embodiment, gaboxadol is the acceptable acid-addition salts form of pharmacy, and acid-addition salts is selected from hydrochlorate or hydrobromate, perhaps is amphion monohydrate form.
In further embodiment, this medicine is a peroral dosage form.Typically, medicine is the solid oral dosage form such as tablet or capsule, or liquid oral dosage form.Therefore, a typical embodiment is the purposes of gaboxadol aspect the medicine that is prepared as treatment human breathing function damage, for example respiratory function damage of old human patients, and this medicine is the gaboxadol that contains 2.5mg to 20mg effective dose in peroral dosage form.This alkali calculates 2.5mg be based on to the effective dose gaboxadol of 20mg.Preferably, gaboxadol is a crystal form.The further embodiment of medicine comprises the effective dose gaboxadol of 2.5mg to 20mg, such as 2.5mg to 4mg, 4mg to 6mg, 6mg to 8mg, 8mg to 10mg, 10mg to 12mg, 12mg to 14mg, 14mg to 16mg, 16mg to 18mg or 18mg to 20mg, for example 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg or 15mg.A typical embodiment is the crystalline gaboxadol of 5mg to 15mg, for example hydrochlorate of gaboxadol.
Use the human patients of gaboxadol treatment in fact can be the population of anyone class, sex, it can be divided into child, adult or old man.Relate to any patient among them in the embodiment.Typically, human patients is selected from adult or gerontal patient.
Treatment is a short term therapy in another embodiment.Treatment is an intermediate period treatment in another embodiment.Treatment is long-term treatment in another embodiment.Treatment is a chronic treatment in another embodiment.
To be gaboxadol be used for long-term treatment in preparation suffers from for example human patients purposes aspect old man patient's the respiratory function damage medicine for example of centric sleep apnea or obstructive sleep apnea of sleep apnea for typical embodiment, and this medicine for example is the peroral dosage form that contains 2.5mg to 20mg effective dose gaboxadol.
In yet another aspect, the present invention relates to treat the method for the human patients of sleep apnea, comprise the gaboxadol that gives described patient's effective dose every day.The present invention further aspect, relate to treating and suffer from for example method of the human patients respiratory function damage of centric sleep apnea or obstructive sleep apnea of sleep apnea, comprise the gaboxadol that gives described patient's effective dose every day.Typically, the effective dose in peroral dosage form comprises 2.5mg to 20mg every day.
The administration time of gaboxadol depends on preparation and/or route of administration according to the present invention.Typically, in most cases be to give gaboxadol, and reach the limit of pharmacokinetics thus as long-term treatment regimen.According to for example crossing per os or the external administration of gastrointestinal by IMU in preceding 10 minutes to 3 hours beginning to sleep the specific length of one's sleep.Therefore, when using gaboxadol to prepare medicine, perhaps when using gaboxadol, typical embodiment is medicinal preparation for oral administration administration or oral administration, wherein in the specific sleep time that begins to sleep preceding 5 minutes to 5 hours, for example gave gaboxadol in preceding 10 minutes to 3 hours immediately beginning to sleep.
On the other hand, the present invention relates to the purposes aspect gaboxadol is used for the treatment of sleep apnea in preparation the medicine of human patients, the gaboxadol that comprises 2.5mg to 20mg effective dose in this medicine, described dosage is effective in the major part (substantial portion) of single sleep cycle.
On the other hand; the present invention relates to gaboxadol is used for the treatment of in preparation and suffers from for example purposes aspect the human patients medicine of centric sleep apnea or obstructive sleep apnea of sleep apnea; comprise the gaboxadol of 2.5mg to 20mg amount in this medicine, described amount is effective in the major part of single sleep cycle.
Another aspect; the present invention relates to treat and suffer from for example method of the human patients respiratory function damage of centric sleep apnea or obstructive sleep apnea of sleep apnea; comprise the effective dose gaboxadol that gives described patient 2.5mg to 20mg amount every day, described amount is effective in the major part of single sleep cycle.
In further embodiment, major part is 40% or more, 50% or more, 60% or more, 70% or more, for example 80% or more.
In further embodiment, single sleep cycle is one to eight hours.Typically, single sleep cycle to four hour, or one to six hour, for example 1,2,3,4,5,6,7 or 8 hour.
In further embodiment, the amount of gaboxadol is for example to prolong release composition from the compositions that is used for sustained release to discharge.
In further embodiment, the amount of 50% to 100% gaboxadol discharged in the three hour time of administration.
In further embodiment, the amount of 80% to 100% gaboxadol discharged in the five hour time of administration.
According to the present invention, gaboxadol can use with the dehydrate of alkali (amphion) or its pharmaceutically-acceptable acid addition or this class salt or alkali or hydrate and solvate forms.The salt of this chemical compound that uses among the present invention is the salt that forms with non-toxic organic or inorganic acids.The example of this class organic salt is the salt that forms with following acid: maleic acid, fumaric acid, benzoic acid, ascorbic acid, succinic acid, oxalic acid, the dimethylene salicylic acid, methanesulfonic acid, ethionic acid, acetic acid, propanoic acid, tartaric acid, salicylic acid, citric acid, gluconic acid, lactic acid, malic acid, mandelic acid, cinnamic acid, citraconic acid, aspartic acid, stearic acid, palm fibre is put acid, the itaconic acid, glycolic, Para-Aminobenzoic, glutamic acid, benzenesulfonic acid and theophylline acetic acid class (theophylline acetic acid), and 8-halo theophylline, for example 8-bromo theophylline.The example of this class inorganic salts is: hydrochlorate, hydrobromate, sulfate, sulfamate, phosphate and nitrate.The all right zwitterionic form of gaboxadol, for example the form of its monohydrate is used.
The preparation of acid-addition salts class of the present invention can be included in and use the acid treatment gaboxadol in the atent solvent, with postprecipitation, separate and the known method recrystallization of optional employing, and can carry out micronization to crystallized product by wet or dry grinding method or other convenient methods if desired, or by solvent emulsion prepared granule.Suitable method is recorded in the EP patent 0000338.
The precipitation of salt typically atent solvent for example inert polar solvents for example alcohol (as, ethanol, 2-propanol and normal propyl alcohol) in carry out, but the mixture of water or water and atent solvent also can adopt.
According to the present invention, gaboxadol is an oral administration, and it can be made into any appropriate format that is used for this class administration.The form of tablet, capsule, powder, syrup or solution for example.Typically, according to purpose of the present invention, gaboxadol in the mode of solid pharmaceutical entity, be preferably tablet or capsule administration.
The method for preparing solid pharmaceutical preparation is well known in the art.Therefore tablet can pass through active component and conventional adjuvant and/or mixing diluents, and compressed mixture prepares in suitable tablet machine subsequently.The example of adjuvant or diluent comprises: corn starch, lactose, Pulvis Talci, magnesium stearate, gelatin, lactose, natural gum etc.Any other adjuvant or additives that can be compatible with active component, for example coloring agent, aromatic, antiseptic etc. all can use.
The suitable formulations form of gaboxadol is described among the WO02/094225 that the applying date is on May 17th, 2002.Any aspect or the specific embodiment in this patent application do not limit the present invention in any way, it be herein medicine or the suitable embodiments of Pharmaceutical composition.
Experimental procedure
Before going to bed, give the gaboxadol of oral 2.5mg to the 20mg dosage of human patients of suffering from sleep apnea.
Claims (24)
1. gaboxadol is used for the treatment of the purposes aspect the human patients medicine of sleep apnea in preparation.
2. gaboxadol is used for the treatment of for example purposes aspect the respiratory function damage medicine of the human patients of centric sleep apnea or obstructive sleep apnea of sleep apnea in preparation.
3. claim 1 or 2 purposes, wherein sleep apnea is a centric sleep apnea.
4. claim 1 or 2 purposes, wherein sleep apnea is an obstructive sleep apnea.
5. claim 1 or 2 purposes, wherein sleep apnea is the mixing of centric sleep apnea and obstructive sleep apnea.
6. each purposes among the claim 1-5, wherein gaboxadol has increased patient's S sleep and has therefore improved respiratory function.
7. each purposes among the claim 1-6, wherein the patient suffers from sleep apnea and depression simultaneously.
8. each purposes among the claim 1-7, wherein gaboxadol is the form of acid-addition salts, for example hydrochlorate or hydrobromate, or amphion hydrate, for example amphion monohydrate or amphion dehydrate.
9. each purposes among the claim 1-8, wherein this medicine is a peroral dosage form.
10. the purposes of claim 9, wherein this medicine is for example tablet or a capsule of solid oral dosage form, or liquid oral dosage form.
11. each purposes among the claim 9-10, wherein this medicine contains the gaboxadol of 2.5mg to 20mg, for example 2.5mg to 4mg, 4mg to 6mg, 6mg to 8mg, 8mg to 10mg, 10mg to 12mg, 12mg to 14mg, 14mg to 16mg, 16mg to 18mg or 18mg to 20mg typically are 5mg to 15mg.
12. each purposes among the claim 1-11, wherein human patients is selected from old people or adult.
13. each purposes among the claim 1-12, wherein said treatment is a short term therapy.
14. each purposes among the claim 1-12, wherein said treatment is an intermediate period treatment.
15. each purposes among the claim 1-12, wherein said treatment is long-term treatment.
16. each purposes among the claim 1-15, wherein said gaboxadol is crystalline.
17. each purposes among the claim 1-16, wherein this medicine contains the gaboxadol of 2.5mg to 20mg, for example contains 5mg to 15mg gaboxadol, and described amount is effective in the major part of single sleep period.
18. the purposes of claim 17, wherein said major part are 50% or more, for example 80% or more.
19. each purposes among the claim 17-18, wherein said single sleep period is one to eight hours.
20. each purposes among the claim 17-19, wherein the amount of gaboxadol discharges from the compositions that is used for sustained release and for example prolongs release.
21. the purposes of claim 20, wherein the gaboxadol of 50% to 100% amount discharged in the three hour time of administration.
22. the purposes of claim 20, wherein the gaboxadol of 80% to 100% amount discharged in the five hour time of administration.
23. treatment suffers from for example method of the respiratory function damage of the human patients of centric sleep apnea or obstructive sleep apnea of sleep apnea, comprises the gaboxadol that gives described patient's effective dose every day.
24. treatment suffers from for example method of the human patients of centric sleep apnea or obstructive sleep apnea of sleep apnea, comprises the gaboxadol that gives described patient's effective dose every day.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200400540 | 2004-04-02 | ||
| DKPA200400540 | 2004-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1942185A true CN1942185A (en) | 2007-04-04 |
Family
ID=36608890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005800119819A Pending CN1942185A (en) | 2004-04-02 | 2005-03-31 | Treatment of impaired respiratory function with gaboxadol |
Country Status (6)
| Country | Link |
|---|---|
| KR (1) | KR20070010136A (en) |
| CN (1) | CN1942185A (en) |
| AR (1) | AR048460A1 (en) |
| EA (1) | EA200601853A1 (en) |
| IL (1) | IL178289A0 (en) |
| ZA (1) | ZA200607427B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108024997A (en) * | 2015-07-17 | 2018-05-11 | 奥维德医疗公司 | With the method for Gaboxadol treatment developmental disorder |
| CN111201022A (en) * | 2017-08-04 | 2020-05-26 | 奥维德医疗公司 | Use of gaboxadol for treating diabetes and related conditions |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3883566A4 (en) | 2018-11-21 | 2022-09-07 | Certego Therapeutics Inc. | Gaboxadol for reducing risk of suicide and rapid relief of depression |
-
2005
- 2005-03-31 KR KR1020067019852A patent/KR20070010136A/en not_active Application Discontinuation
- 2005-03-31 EA EA200601853A patent/EA200601853A1/en unknown
- 2005-03-31 CN CNA2005800119819A patent/CN1942185A/en active Pending
- 2005-03-31 ZA ZA200607427A patent/ZA200607427B/en unknown
- 2005-04-01 AR ARP050101300A patent/AR048460A1/en unknown
-
2006
- 2006-09-25 IL IL178289A patent/IL178289A0/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108024997A (en) * | 2015-07-17 | 2018-05-11 | 奥维德医疗公司 | With the method for Gaboxadol treatment developmental disorder |
| CN111201022A (en) * | 2017-08-04 | 2020-05-26 | 奥维德医疗公司 | Use of gaboxadol for treating diabetes and related conditions |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070010136A (en) | 2007-01-22 |
| EA200601853A1 (en) | 2007-02-27 |
| ZA200607427B (en) | 2009-02-25 |
| IL178289A0 (en) | 2007-03-08 |
| AR048460A1 (en) | 2006-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007530604A (en) | Respiratory dysfunction treatment | |
| US20120101073A1 (en) | Novel Method For Treating Breathing Disorders or Diseases | |
| US20150272934A1 (en) | Use of cse inhibitors for the treatment of cutaneous injuries or conditions and sleep-related breathing disorders | |
| US20080261931A1 (en) | Method and Means of Preventing and Treating Sleep Disordered Breathing | |
| JP5712452B2 (en) | Methods and compositions for reducing risk associated with administration of opioid analgesics in patients with diagnosed respiratory disease or patients with undiagnosed respiratory disease | |
| WO2012166909A1 (en) | Compositions and methods for treating breathing control disorders or diseases | |
| EP3206685B1 (en) | Prevention or treatment of sleep disorders using dexmedetomidine formulation | |
| CN1917874A (en) | Method of treating and diagnosing sleep disordered breathing using zonisamide and means for carrying out the method | |
| JP2009537553A5 (en) | ||
| KR20150011379A (en) | Methods and compositions for administration of oxybutynin | |
| CN1942185A (en) | Treatment of impaired respiratory function with gaboxadol | |
| US10682343B2 (en) | Snoring treatment | |
| WO2016061554A1 (en) | Synergistic composition of known, safe pharmaceuticals for use in insomnia and a method of treatment thereof | |
| US20060128605A1 (en) | Preventives/remedies for snore or respiratory disturbances during sleep | |
| CN1853619A (en) | Use of agomelatin in the manufacture of a medicament for the treatment of bipolar disorders | |
| JP2010505844A (en) | S-nitrosothiol compounds and related derivatives | |
| US20230270724A1 (en) | PDE3 inhibitors for treating viral infections | |
| JP2006191933A (en) | Preventive and remedy for snoring or respiratory disorder during sleep | |
| WO2013037883A1 (en) | New use of melatonine | |
| CN116916909A (en) | Combination of reboxetine and a Muscarinic Receptor Antagonist (MRA) for the treatment of sleep apnea | |
| JP2022529290A (en) | Methods and Compositions for Treating Respiratory Arrhythmias | |
| Mani | Noninvasive ventilation for hypercapnic respiratory failure in COPD and initial post-support deterioration of pH and PaCO2 may not predict failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1104920 Country of ref document: HK |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1104920 Country of ref document: HK |